{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:22:28Z","timestamp":1787239348040,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1093\/eurheartj\/ehs084","type":"journal-article","created":{"date-parts":[[2012,5,25]],"date-time":"2012-05-25T20:59:22Z","timestamp":1337979562000},"page":"1451-1458","source":"Crossref","is-referenced-by-count":91,"title":["Antisense oligonucleotides for the treatment of dyslipidaemia"],"prefix":"10.1093","volume":"33","author":[{"given":"Maartje E.","family":"Visser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,24]]},"reference":[{"key":"key\n\t\t\t\t20170325061835_EHS084C1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment III) final report","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment III)","year":"2002","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170325061835_EHS084C2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key\n\t\t\t\t20170325061835_EHS084C3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1388-1981(99)00083-9","article-title":"Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver","volume":"1440","author":"Davis","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"key\n\t\t\t\t20170325061835_EHS084C4","first-page":"2863","article-title":"Familial hypercholesterolemia","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Goldstein","year":"2001","edition":"8th ed"},{"key":"key\n\t\t\t\t20170325061835_EHS084C5","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/01.ATV.0000176191.64314.07","article-title":"Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia","volume":"25","author":"Sankatsing","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170325061835_EHS084C6","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00018-005-4473-0","article-title":"Familial hypobetalipoproteinemia: genetics and metabolism","volume":"62","author":"Schonfeld","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"key\n\t\t\t\t20170325061835_EHS084C7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2005.06.018","article-title":"Hepatic steatosis and insulin resistance: does etiology make a difference?","volume":"44","author":"Lonardo","year":"2006","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20170325061835_EHS084C8","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.atherosclerosis.2007.05.003","article-title":"Molecular diagnosis of hypobetalipoproteinemia: an ENID review","volume":"195","author":"Tarugi","year":"2007","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20170325061835_EHS084C9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0022-2275(20)38425-X","article-title":"Plasma very low density lipoproteins contain a single molecule of apolipoprotein B","volume":"29","author":"Elovson","year":"1988","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170325061835_EHS084C10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key\n\t\t\t\t20170325061835_EHS084C11","first-page":"601","volume-title":"Cardiovascular Therapeutic Applications in Antisense Drug Technology; Principles, Strategies and Applications","author":"Crooke","year":"2008","edition":"2nd ed"},{"key":"key\n\t\t\t\t20170325061835_EHS084C12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","author":"Crooke","year":"2005","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170325061835_EHS084C13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1194\/jlr.M011791","article-title":"Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice","volume":"52","author":"Mullick","year":"2011","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170325061835_EHS084C14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20170325061835_EHS084C15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/0003088-200948010-00003","article-title":"Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2\u2032-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe","volume":"48","author":"Yu","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20170325061835_EHS084C16","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1194\/jlr.M300094-JLR200","article-title":"CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans","volume":"44","author":"Chandler","year":"2003","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170325061835_EHS084C17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170325061835_EHS084C18","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/eurheartj\/ehr148","article-title":"Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia","volume":"32","author":"Akdim","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170325061835_EHS084C19","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55","author":"Akdim","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170325061835_EHS084C20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170325061835_EHS084C21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"key\n\t\t\t\t20170325061835_EHS084C22","first-page":"898","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease","volume":"31","author":"Stein","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170325061835_EHS084C23","doi-asserted-by":"crossref","first-page":"E492","DOI":"10.1016\/S0735-1097(11)60492-0","article-title":"Apolipoprotein B synthesis inhibition by mipomersen reduces LDL-C when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia","volume":"57","author":"Tardif","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170325061835_EHS084C24","doi-asserted-by":"crossref","first-page":"E504","DOI":"10.1016\/S0735-1097(11)60504-4","article-title":"Safety and efficacy of mipomersen administered as add-on therapy in patients with hypercholesterolemia and high cardiovascular risk","volume":"57","author":"Cromwell","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170325061835_EHS084C25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2310\/7750.2009.08077","article-title":"Postinflammatory hyperpigmentation","volume":"13","author":"Taylor","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"key\n\t\t\t\t20170325061835_EHS084C26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170325061835_EHS084C27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","author":"Visser","year":"2010","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170325061835_EHS084C28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170325061835_EHS084C29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"key\n\t\t\t\t20170325061835_EHS084C30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"key\n\t\t\t\t20170325061835_EHS084C31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20170325061835_EHS084C32","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin Chem"},{"key":"key\n\t\t\t\t20170325061835_EHS084C33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20170325061835_EHS084C34","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1093\/nar\/gkq457","article-title":"Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates","volume":"38","author":"Straarup","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"key\n\t\t\t\t20170325061835_EHS084C35","doi-asserted-by":"crossref","first-page":"e10682","DOI":"10.1371\/journal.pone.0010682","article-title":"A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo","volume":"5","author":"Gupta","year":"2010","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170325061835_EHS084C36","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170325061835_EHS084C37","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"key\n\t\t\t\t20170325061835_EHS084C38","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170325061835_EHS084C39","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/33\/12\/1451\/9629729\/ehs084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T04:54:34Z","timestamp":1642308874000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehs084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,24]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,5,24]]},"published-print":{"date-parts":[[2012,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehs084","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5,24]]}}}